KINOMEscan released scanLIPID, a commercial collection of human lipid kinase assays including PI3K, PI4K, PIP, and clinically relevant mutants.
Lipid kinases have emerged as attractive drug targets as a growing body of evidence implicates them as key players in several disease processes, including cancer.
Using KINOMEscan’s high throughput kinase profiling platform, researchers can profile compounds in a standardized assay format against the largest human lipid kinase panel available, according to KINOMEscan.
Published in Drug Discovery & Development magazine: Vol. 12, No. 4, April, 2009, p.18.
